Related Experiment Video

Updated: Mar 18, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

613

Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor

Shruti Rakesh Tiwari1, Prasun Mishra2, Jame Abraham1

  • 1Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.

Clinical Breast Cancer
|July 14, 2016
PubMed

Insights

Neratinib, a targeted therapy, shows promise for HER2-amplified breast cancer by inhibiting multiple HER receptors. This review covers its efficacy, safety, and clinical use in various breast cancer settings.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • HER2 gene amplification occurs in 20-25% of breast cancers.
  • Targeted therapy for HER2-amplified breast cancer improves survival.
  • Neratinib is an oral pan HER inhibitor targeting EGFR, HER2, and HER4.

Purpose of the Study:

  • To review Phase I, II, and III data for neratinib in breast cancer.
  • To discuss ongoing clinical trials of neratinib in breast cancer.
  • To elaborate on neratinib's side effect profile and clinical use guidelines.

Main Methods:

  • Review of available Phase I, II, and III clinical trial data.
  • Analysis of neratinib's efficacy in metastatic, adjuvant, neoadjuvant, and extended adjuvant settings.
  • Evaluation of safety and side effect profiles.

Main Results:

  • Neratinib demonstrates efficacy in various breast cancer treatment settings.
  • Data from clinical trials inform its use in HER2-amplified breast cancer.
  • Understanding the side effect profile is crucial for clinical practice.

Conclusions:

  • Neratinib is a valuable targeted therapy option for HER2-amplified breast cancer.
  • Further clinical trials are ongoing to establish its full potential.
  • Guidelines for neratinib use are essential for optimizing patient outcomes.
Keywords:
HER2 directed therapyHuman epidermal growth factor receptor 2Neratinib

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
620
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
88.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K